Kornimate/medical-research-clean huggingface dataset:
role of oxytocin in telling and detecting lies

Conditions: Dyssocial Behavior

Summary: the investigators are interested in the impact of intranasal oxytocin in unethical behavior.

the objective of this project is to further explore the role of oxytocin in moral judgment and ethical behavior. oxytocin is a peptide hormone produced in a variety of hypothalamic neurons. it is released into the brain or brought into general circulation through sensory stimuli in a pulsatile fashion. in social psychology research, oxytocin is hypothesized to coordinate both the causes and effects of positive social interactions in a biofeedback loop.

Eligibility criteria:
inclusion criteria: * male exclusion criteria: * _____ _____bp \> 130/85, hrt \> 95 (can be included at discretion of study physician/designee) * _____history of seizures * _____neurological disorder * _____current psychiatric disorder * _____previous psychiatric disorder (can be included at discretion of pi) * date last episode (if \> 1 year, include; if \<1 year, at discretion of pi) * _____current use of psychoactive drugs * _____previous use of psychoactive drugs (can be included at discretion of pi) _____date last medicated_____ _____type of medication___________________________________ * _____current use of anticoagulants * _____current use of corticosteroids * _____previous head trauma (can be included at discretion of pi) * _____alcoholism or substance abuse * _____carcinoma of the breast or prostate * _____renal or hepatic diseases * _____chronic lung diseases * _____cancer * _____liver problems * _____hypertension/cardiac diseases * _____cardiovascular disease * _____nephritis * _____diabetes (use of insulin) /obesity * _____endocrine disease or malignancy * _____asthma (can be included as discretion of study physician/designee, if episodes are infrequent, nonmedicated, and no active problems at time of study) * medication * frequency of episodes____ _____date of last episode_____ * _____migraines(can be included as discretion of study physician/designee, if episodes are infrequent, nonmedicated, and no active problems at time of study) * medication _____frequency of migraines_____ _____date of last migraine_____ * _____high levels of physical contact with women or children
virtual reality therapy in cardiology

Conditions: Cardiovascular Diseases; Coronary Artery Disease; Depressive Symptoms; Mood Disorders; Anxiety; Stress

Summary: this study evaluates the effectiveness of virtual reality (vr) therapy in the treatment of depression and anxiety symptoms in patients undergoing second stage of cardiac rehabilitation. half of the study group will receive vr therapy (vr group) as an addition to cardiologically monitored physical training. the other half of the group (control group) will receive schultz autogenic training as a standard supplement to cardiological training

cardiologically monitored physical training in second stage of cardiac rehabilitation leads to the improvement in the physical capacity and overall fitness of the patients with cardiovascular diseases, allowing restoration of independence in daily functioning. psychological support is required in order to reduce the negative psychological symptoms related to the heart disease. in this study the investigators want to assess the effectiveness of the virtual reality (vr) therapy compared to standard psychological support (schultz autogenic training).thanks to using head mounted display (vr goggles) and the phenomenon of total immersion vr therapy allows to completely separate the patient from the hospital environment, provides an intense visual, auditory and kinesthetic stimulation. depending on the stage of therapy it can have a calming and mood-improving effect or, in another part of the therapy, it can motivate the patient to the rehabilitation process. the additional aim of the vr therapy is to help the patients regain their emotional balance, let them recognize their psychological resources and trigger the natural recovery mechanisms. the aims of the project: 1. the evaluation of the influence of vr therapy on the depressive symptoms and the anxiety level of the patients undergoing second stage of cardiac rehabilitation. 2. the evaluation of the influence of vr therapy on the stress level of the patients undergoing second stage of cardiac rehabilitation.

Eligibility criteria:
inclusion criteria: * coronary artery disease; * the second stage of cardiac rehabilitation conducted in outpatient settings; exclusion criteria: * cognitive impairment (mmse\<24); * inability to self-complete the research questionnaires; * presence of the following issues at the time of the examination or in the medical data: disturbances of consciousness, psychotic symptoms or other serious psychiatric disorders; * initiation of psychiatric treatment during the research project; * contraindications for virtual therapy (epilepsy, vertigo, eyesight impairment); * the patient's refusal at any stage of the research project.

Keywords: virtual reality cardiac rehabilitation psychotherapy cardiac surgery depression anxiety stress
rise for nurse preceptors

Conditions: Mental Health; Resilience; Self-Compassion; Empowerment; Well-Being, Psychological; Burnout, Healthcare Workers

Summary: the purpose of this study is to determine whether rise for nurse preceptors has a significant impact on nurse preceptors' burnout, resilience, insight, self-compassion, and empowerment, as well as mental well-being, in their personal lives and their working environment.


Eligibility criteria:
inclusion criteria: 1. adult ≥ 18 years old 2. licensed as an rn 3. employed by adventhealth rocky mountain region 4. completion of the adventhealth preceptor training 5. has precepted ≥ 48 hours within the past calendar year in an adventhealth hospital setting or outpatient emergency center 6. able to speak, read, and understand english fluently 7. able to provide informed consent 8. willing and able to comply with all study procedures and requirements for the duration of the study. exclusion criteria: 1. has precepted \< 48 hours within the past calendar year 2. does not pass the brief risk assessment in the pre-intervention introduction meeting with the lmhc facilitator 3. unwilling or unable to comply with all study procedures and requirements for the duration of the study.
translating an efficacious illness management intervention for youth with asthma

Conditions: Asthma in Children

Summary: the propose of the study is to test the effectiveness of reach for control (rfc) as compared to michigan match to improve asthma symptoms, asthma management and lung functioning and to decrease ed visits and admissions for youth with poorly controlled asthma when integrated into hospital emergency departments and delivered by community health workers. the study is a hybrid implementation-effectiveness design and will test rfc for use in real world, public healthcare settings.

the study was conducted in the emergency department at children's hospital of michigan; chm). 170 adolescents with poorly controlled asthma and their primary caregivers will be enrolled. prior to the covid-19 pandemic, families were randomly assigned to six months of home-based family treatment consisting of either rfc or michigan match , a model program endorsed by the state of michigan for treatment of poorly controlled asthma. subsequently, all intervention content in both arms was delivered by telehealth. treatment content of rfc consists of weekly sessions focusing on asthma education, asthma management skills, improving home-school community for asthma, access to care and case management. match includes asthma education but is less intensive and does not focus on family management skills. treatment was provided by community health workers (chws) employed by a community agency providing match as their standard of care. consent and data collection was completed at baseline with additional data collection visits at 6, 12 and 18 months after baseline. data collection was completed by project research assistants and consists of questionnaires and interviews with the adolescent and parent to assess asthma management, asthma symptoms and hospital utilization. the data analyses were intent-to-treat, meaning that all randomized participants are included regardless of the intervention dose received. trial data were analyzed using linear mixed effect models.

Eligibility criteria:
inclusion criteria: adolescent/parent: 1. child aged 12 years, 0 months to 16 years, 11 months 2. moderate to severe persistent asthma 3. child seen in the chm emergency department for treatment of asthma exacerbation 4. child has experienced 2 or more ed visits and/ or inpatient admissions in prior 12 months (i.e. poorly controlled asthma) 5. parent/ legal guardian willing to participate in home-based family treatment 6. child and family resides within 20 miles of chm (allows for home-based data collection and intervention) exclusion criteria: adolescent/parent: 1. child is currently in an out-of-home placement 2. schizophrenia or other psychosis on the part of the youth or parent 3. current suicidality or homicidality on the part of the youth or parent 4. cognitive impairment or learning disability that prevents comprehension of research measures on the part of parent or youth

Keywords: asthma management, adolescents
nutritional support for rehabilitation in parkinsonism

Conditions: Disability Physical

Summary: this randomized, trial will tested the hypothesis that nutritional supplementation with whey protein, essential amino acids - mainly leucine - vitamin d and calcium would increase the efficacy of physical rehabilitation in old adults suffering from parkinson's disease o parkinsonism


Eligibility criteria:
inclusion criteria: * parkinson's disease o parkinsonism * admission for physical rehabilitation * informed consent exclusion criteria: * any malignant disease during the last five years * known kidney failure (previous glomerular filtration rate \<30 ml/min); * known liver failure (child b or c) * psychiatric disease * endocrine disorders associated with disorders of calcium metabolism (excluding osteoporosis) * indications related to the study product: more than 10 μg (400 iu) of daily vitamin d intake from medical sources more than 500 mg of daily calcium intake from medical sources. adherence to a high energy or high protein diet up or use of protein containing or amino acid containing nutritional supplements up to three months before starting the study. * known allergy to milk, milk products or other components of the proposed interventions * indication to or ongoing artificial nutrition support * inclusion in other nutrition intervention trials * investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements * refusal
a study of ly3415244 in participants with advanced solid tumors

Conditions: Solid Tumor

Summary: the goal of this study is to evaluate the safety of ly3415244, a pd-l1/tim-3 bispecific antibody, administered as monotherapy to participants with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * for phase 1a/b, histologic or cytologic confirmation of advanced solid tumor. * for phase 1a/b, biopsy of tumor samples are required. newly obtained core or excisional biopsy of a tumor lesion prior to study enrollment and undergo a biopsy procedure during the study. * phase 1a, prior anti-pd-1 or anti-pd-l1 therapy or other immunotherapy is allowed. * phase 1b, prior anti-pd-1 or anti-pd-l1 therapy is required where anti-pd-1 or anti-pd-l1 is standard of care in respective tumor types if the following criteria are met: * must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy * must have completely recovered to baseline level prior to screening from any adverse events (aes) that occurred from receiving prior immunotherapy * must not have experienced a grade ≥3 immune-related ae or immune related neurologic or ocular ae, pneumonitis or cardiomyopathy of any grade while receiving prior immunotherapy * must not have required immunosuppressive agent, other than corticosteroids for the management of an adverse event and not currently require maintenance doses of \>10 milligrams (mg) prednisone (or equivalent) per day * must have at least 1 measurable lesion as defined by the response evaluation criteria in solid tumors (recist 1.1). * have adequate organ function. * have an estimated life expectancy ≥12 weeks, in the judgement of the investigator. exclusion criteria: * have symptomatic central nervous system (cns) malignancy or metastasis not requiring concurrent treatment, including but not limited to surgery, radiation, corticosteroids and/or anticonvulsants to treat cns metastases, and their disease is asymptomatic and radiographically stable for at least 30 days. * have received a live vaccine within 30 days before the first dose of study treatment. * if female, is pregnant, breastfeeding, or planning to become pregnant. * have a history or current evidence of any condition, therapy, or laboratory abnormality that might interfere with the participant's participation. * have moderate or severe cardiovascular disease. * have a serious concomitant systemic disorder that would compromise the participant's ability to adhere to the protocol, including known infection with human immunodeficiency virus (hiv), active hepatitis b virus (hbv), active hepatitis c virus (hcv), active autoimmune disorders, or prior documented severe autoimmune or inflammatory disorders requiring immunosuppressive treatment. * use of escalating or chronic supraphysiologic doses of corticosteroids or immunosuppressive agents (such as, cyclosporine). \[use of topical, ophthalmic, inhaled, and intranasal corticosteroids permitted\]. * bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection. * evidence of interstitial lung disease or noninfectious pneumonitis.

Keywords: tim-3 pd-l1
study of ngm621 in participants with geographic atrophy

Conditions: Geographic Atrophy

Summary: this is a multi-center evaluation of ngm621 in an open-label, single-dose and multiple-dose escalation study in participants with geographic atrophy secondary to age-related macular degeneration.


Eligibility criteria:
inclusion criteria: 1. ga lesion size in the study eye of \>=2.5 mm² as assessed by the central reading center 2. bcva - 54 to 4 letters (20/80 to 20/400 snellen equivalent) using the standard etdrs (early treatment of diabetic retinopathy study) in the study eye at the screening and baseline visits; the fellow eye must have a bcva of at least 69 letters (snellen equivalent 20/40) at the screening and baseline visits exclusion criteria: 1. ga in either eye because of cause other than amd 2. history or evidence of glaucoma or ocular hypertension in either eye as defined by investigator 3. visual impairment in the study eye due to causes other than ga 4. spherical equivalent of the refractive error in the study eye demonstrating more than -6 diopters of myopia (prior to cataract or refractive surgery) other protocol-defined inclusion/exclusion criteria could apply.
intravitreal aflibercept in wet age related macular degeneration patients with an incomplete response to routine ranibizumab injections

Conditions: Age Related Macular Degeneration

Summary: shift-2 is a national, multi-center, non-randomized, open label trial of aflibercept in patients with wet age related macular degeneration who have incomplete response with routineranibizumab treatment.


Eligibility criteria:
inclusion criteria: note: subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study 1. age \>50 years 2. active primary subfoveal choroidal neovascularization (cnv) lesions secondary to amd including juxtafoveal lesions that affect the fovea as evidenced by fluorescein angiography in the study eye 3. presence of intra or sub retinal fluid on sdoct in the study eye 4. current treatment with uninterrupted routine (q35 +/- 7 days) ranibizumab started at least 3 months before baseline (week 0), having received at least 3 consecutive ranibizumab injections and no more than 24 injections maximum, with all ranibizumab injection intervals being 35 +/- 7 days apart 5. etdrs bcva 20/30 and 20/320 (letter score of 78 to 25) in the study eye exclusion criteria: subjects presenting with any of the following will not be included in the study: 1. presence of purely serous pigment epithelial detachment in the study eye 2. any scarring or fibrosis involving the center of the fovea in the study eye 3. prior ocular or systemic treatment/surgery for wet amd other than ranibizumab ivi monthly (in study the eye) 4. prior prn or treat and extend treatment with ranibizumab ivi between 3 to 24 months before baseline (week 0) in the study eye 5. prior treatment with systemic anti-vegf therapy within the last 6 months in the study eye 6. history of vitreous hemorrhage within the last 6 months in the study eye 7. prior vitrectomy in the study eye 8. history of retinal detachment in the study eye 9. history of macular hole of stage 2 and above in the study eye 10. presence of retinal pigment epithelial tears or rips involving the macula in the study eye. 11. any intraocular or periocular surgery/invasive procedure during the previous 6 months except lid surgery in the study eye 12. prior trabeculectomy or other filtration surgery in the study eye 13. uncontrolled glaucoma (≥ 25mmhg despite treatment with anti-glaucoma medications) in the study eye 14. aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a result of a yttrium aluminum garnet (yag) posterior capsulotomy) in the study eye. 15. scheduled for intraocular surgery during the study period in the study eye 16. concurrent retinal disease (i.e. diabetic retinopathy, retinal vein occlusion, retinal detachment, uveitis) in the study eye 17. history of ocular or periocular infection/inflammation in the study eye within the last 4 weeks of screening 18. pregnant or breastfeeding

Keywords: age related macular degeneration, wet aflibercept
safety study of intravenous 6β-naltrexol (aiko-150) in opioid-dependent subjects

Conditions: Opiate Addiction

Summary: the purpose of this study is to evaluate the safety and efficacy of intravenous 6β-naltrexol administered to opiate dependent subjects


Eligibility criteria:
inclusion criteria: * opiate dependent males and females age 21-45 on stable doses of methadone * fluent english speaker * willing and able to give written consent exclusion criteria: * pregnancy or lactation for more details contact the research clinic.

Keywords: naloxone 6β-naltrexol opioid-dependent pharmacokinetics peripheral effects of withdrawal central effects of withdrawal
fluidotherapy in patients with distal radius fractures

Conditions: Distal Radius Fractures; Edema Arm; Pain

Summary: distal radius fractures are the most common fractures when looking at upper extremity fractures. the incidence of distal radius fractures is increasing day by day, and when looking at the databases of various countries, its annual prevalence reaches 70,000 in the uk and 640,000 in the usa. most of these fractures are related to osteoporosis and require appropriate treatment. if not, it causes loss of work force, permanent disability, and limitation in daily activities. fluidotherapy has also proven to be effective in reducing hand edema in patients with carpal tunnel syndrome and stroke, examining its effect on nerve conduction velocities, and warming hypothermic patients. compared to these treatment methods, fluid therapy reduces both joint capsule and muscle temperature by 9°c and 5.7°c, respectively. has been reported to increase.

reducing pain and edema after distal radius fracture is an important part of postoperative rehabilitation. various massage and mobilization methods were applied to this patient population in the postoperative period. in a recent study evaluating the effectiveness of whirlpool treatment, it was reported that studies on the effectiveness of fluidotherapy are also needed. there is no study in the literature evaluating the effectiveness of fluidotherapy in the postoperative rehabilitation program in patients who underwent surgery for distal radius fractures. this study aimed to evaluate the effect of adding fluidotherapy to the early rehabilitation program on pain, edema, joint range of motion and functionality after the cast is removed in patients who received conservative cast treatment due to distal radius fracture.

Eligibility criteria:
inclusion criteria: -treating with a cast due to distal radius fracture being over 18 years old exclusion criteria: * presence of polytrauma * history of previous limb-related surgery * hemiplegia in the involved limb * contracture in the involved limb * arterial and venous occlusions * lymphatic system disorders * heart and circulatory system disorders * hepatitis, measles, sepsis infectious diseases or fever * open wound on the applied hand.

Keywords: distal radius fractures edema pain physical therapy fluidotherapy
efficacy and safety of mydriatic microdrops for retinopathy of prematurity screening

Conditions: Retinopathy of Prematurity

Summary: the purpose is to test the hypothesis that microdrop instillation of combined phenylephrine 1.67% and tropicamide 0.33% eyedrops causes at least equal mydriasis compared with standard drop instillation of the same mydriatic regimen, which constitutes routine care for pupil dilation during retinopathy of prematurity (rop) screening in our neonatal intensive care unit. comparison, also, will be made to the subsequent adverse events and the drug concentration in peripheral blood samples.

a non-inferiority, crossover, randomized controlled trial will be conducted for this purpose. participants will be randomly assigned to receive either a) microdrops on their first and standard drops on their second screening examination a week later (m/s group), or b) standard drops first and microdrops a week later (s/m group). microdrops (6.5 μl) will be instilled using a calibrated micropipette, while standard drops (28-34 μl) will be instilled directly through the commercially available plastic multi-dose mydriatic dropper bottle.

Eligibility criteria:
inclusion criteria: preterm infants undergoing screening for rop, i.e. * infants with ga \< 32 weeks and/or bw \< 1501 grams * infants of greater ga and bw with comorbidities, e.g. sepsis, prolonged need for oxygen supplementation etc., as recommended by the attending neonatologist exclusion criteria: * unstable clinical condition * severe cardiovascular disease * congenital anomalies * clinical syndromes * inotropes' intake during the week prior to enrollment * traumatic apoptosis of the corneal epithelium * corneal ulcer * anatomical variations of the anterior segment * infants that are outpatients at the commencement of rop screening

Keywords: microdrops mydriasis dilating drops phenylephrine tropicamide retinopathy of prematurity rop screening